Unifocal lesions on mammogram and MRI (small satellite lesions adjacent to the tumor are accepted as long as it is suitable for local excision to be determined by the participating centre)
World Health Organization performance status ≤ 2
Life expectancy ≥ 5 years
Written informed consent
You may not be if
Distant metastases
Lobular invasive carcinomas
Pure Ductal Carcinoma in situ (DCIS) without invasive tumor
Grade III in biopsy
Triple negative tumors
HER2neu positive tumors
Lymphvascular invasion in biopsy
TNM pathologic stage N1-3
pN+ (micro- or macrometastases)
Multicentric / multifocal disease on mammogram or MRI
Diffuse calcifications on mammogram (Birads 3, 4 or 5)
Prior treatment for the protocol tumor (no surgery, no neoadjuvant chemotherapy or neoadjuvant hormonal therapy, no previous radiotherapy)
Previous contralateral breast cancer
Other neoplasms in the last 5 years with the exception of:
Basal cell carcinoma of the skin
Adequately treated carcinoma in situ of the cervix
Planned oncoplastic resection with tissue displacement
No social security affiliation/health insurance
Participation in another clinical trial that interferes with the locoregional treatment of this protocol
It is expected that dosimetric constraints cannot be met, ie, lung/heart constraints or if the ratio PTV/ipsilateral breast \>30%
Clareo Health | Pre- Versus Postoperative Accelerated Partial Breast Irradiation
